We are live on ! Find out more

MANE

Veradermics Inc

MANE

Market cap $4.92B

117.82 USD

+2.82

2.45%

At close Updated Sep 29, 4:00 PM EDT

1 day

2.45%

5 days

-0.25%

1 month

19.72%

3 months

-4.66%

6 months

93.62%

Year to date

212.11%

1 year

212.11%

5 years

212.11%

10 years

212.11%

About: Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.

Employees: 21

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 33.3%

Neutral 66.7%

Negative 0%

Veradermics: Buy Before The Catalysts

Veradermics is positioned for significant upside in the coming years as its lead asset, VDPHL01, approaches pivotal Phase 3 readouts and potential FDA approval. MANE's non-hormonal, extended-release oral minoxidil demonstrates superior efficacy and safety, especially for women, with strong clinical results and no major adverse events. With $819.9 million in cash and a manageable burn rate, MANE appears fully funded through its anticipated 2028 commercial launch, minimizing dilution risk.

Veradermics: Buy Before The Catalysts

Veradermics, Incorporated (MANE) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript

Veradermics, Incorporated (MANE) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript

Veradermics, Incorporated (MANE) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript

Veradermics to Present at Upcoming September Investor Conferences

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that company management will participate in the following upcoming investor conferences in September: Wells Fargo 21st Annual Healthcare Conference Investor Meetings: Tuesday, September 8, 2026 in Boston, MA Citi's 2026 Biopharma Back to School Conference Presentation: Wednesd.

Veradermics to Present at Upcoming September Investor Conferences

Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent corporate and clinical progress. “In the second quarter of 2026, we made significant advancements in the development of VDPHL01 for female pattern hair loss, supporting key milestones for the p.

Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics: VDPHL01 Looks Promising Enough On Paper

MANE's main drug candidate is VDPHL01. This asset already has encouraging male and female data for hair loss. However, VDPHL01 still needs pivotal data to make it ready for a potential FDA submission. If approved, VDPHL01 would compete as a cash-pay prescription treatment for pattern hair loss, which would let MANE tap into a sizeable TAM.

Veradermics: VDPHL01 Looks Promising Enough On Paper

Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302' in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the Phase 2/3 Study ‘302' of VDPHL01 in male patients with mild-to-moderate pattern hair loss. The subgroup analysis data were shared in a poster presentation on July 16, 2026, and will be shared in an oral presentation on July 17, 2026, during th.

Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302' in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy

Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months

Veradermics Incorporated (NYSE:MANE) on Wednesday released topline results from an open-label Phase 2 trial evaluating its experimental VDPHL01 in women with mild-to-moderate pattern hair loss.

Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months

Veradermics, Incorporated (MANE) Discusses Positive Female Results From Phase II Study of VDPHL01 for Pattern Hair Loss Transcript

Veradermics, Incorporated (MANE) Discusses Positive Female Results From Phase II Study of VDPHL01 for Pattern Hair Loss Transcript

Veradermics, Incorporated (MANE) Discusses Positive Female Results From Phase II Study of VDPHL01 for Pattern Hair Loss Transcript

Veradermics Hair Loss Pill Shows Strong Phase II Signal in Women

Veradermics NYSE: MANE said results from the female arms of Study 207, a phase II open-label trial of VDPHL01 for mild to moderate pattern hair loss, showed what company executives described as a strong proof-of-concept signal for the oral treatment.

Veradermics Hair Loss Pill Shows Strong Phase II Signal in Women

PayPal, Veradermics, Alibaba And Other Big Stocks Moving Higher On Wednesday

U.S. stocks were higher, with the Dow Jones index gaining around 100 points on Wednesday.

PayPal, Veradermics, Alibaba And Other Big Stocks Moving Higher On Wednesday

See News Rankings

Price charts implemented using Lightweight Charts™